Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C ( δPKC ) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) In Vitro Delcasertib (KAI-9803) is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed “cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed “carrier peptide”) via a disulfide bond. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Delcasertib (KAI-9803, a single intraperitoneal injection) in mice results in the selective inhibition of PKC translocation in the liver, kidney, lung, heart, and brain . Delcasertib (KAI-9803) administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction . Delcasertib (KAI-9803) has been studied for the prevention of reperfusion injury in patients undergoing angioplasty after acute myocardial infarction. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Six-week-old male Crl:CD(SD) rats . Dosage: 1 mg/kg (Pharmacokinetic Analysis). Administration: Via the femoral vein. Result: The distribution to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57. Form:Solid IC50& Target:δPKC